Adolescent girls’ male partners are not all much older, much wealthier ‘sugar daddies’
US doctors’ organisation endorses event-based PrEP for the first time
PrEP for female sex workers: non-judgemental attitudes and community involvement are keys to success
Dolutegravir-based ART effective and safe for HIV-positive people taking standard TB treatment
Neuropsychiatric side-effects lead only 1 in 40 to drop dolutegravir, French study shows
Starting treatment on the day of HIV diagnosis is acceptable and feasible for Thai patients
PrEP use taking off in Thailand and Vietnam
People with HIV receiving methadone and HIV drugs spend less time with detectable viral load
Studies show dolutegravir monotherapy is an unsafe switch option
HIV infection is a risk factor for liver fat accumulation
Diarrhoea continues to affect the quality of life of people with HIV in the modern treatment era
PrEP spreads across Africa – slowly
Young adults with life-long HIV have a higher risk of cancer
Increase in STIs in PrEP users is concentrated in a minority of men and is partly due to more STI screening
Unintended pregnancies and desire for children: reproductive health needs of women living with HIV
Most adolescent PrEP users in US are young women
Amsterdam 2018: the Undetectable conference
Dolutegravir brings faster viral suppression in late pregnancy
